Alkermes
artistry phase efficacy expansion initiated following determination phase dose week lead in followed by combination of and either or cohorts a to a dose cohorts to dose phase efficacy expansion in solid tumors initiated at combination selected efficacy expansion in select solid tumors where previous responses were observed primary objectives safety and efficacy in combination with subcutaneous recommended phase dose administered once weekly administered once every three weeks secondary objectives include clinical profile and immunogenicity clinical pharmacodynamic effects all parts anti tumor activity phase and objective response rate and dor duration of response phase as fae | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
80 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Results
June 2021
artistry phase efficacy expansion initiated following determination of subcutaneous | Alkermes
Related slides by other companies
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
argenx SE
Results
June 2023
for multifocal motor neuropathy advancing phase study to cohort a | argenx SE
BioNTech
Results
March 2022
phase expansion cohorts ongoing | BioNTech
Kymera
Investor Presentation
June 2023
phase dose and expansion trial to evaluate in adult patients with liquid and solid tumors | Kymera
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io